Sonelokimab in Psoriatic Arthritis

Trial
100%75%50%25%0%Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jun 24 • YES 58.0%Jun 25 • YES 73.0%Jun 29 • YES 73.6%Jun 30 • YES 73.6%Jul 1 • YES 63.1%Jul 2 • YES 83.1%Jul 3 • YES 83.1%Jul 4 • YES 9.7%Jul 5 • YES 9.7%Jul 6 • YES 40.5%Jul 7 • YES 93.2%
ResolvedYES
Oracle Evidence
Medical-journal style anatomical illustration of psoriatic arthritis in an inflamed finger joint

Psoriatic Arthritis

Psoriatic arthritis is an immune-driven disease that can inflame both joints and skin. ACR50 tracks a meaningful drop in joint symptoms by Week 16.

1US adults: 1.0M2US prevalence: 0.3%3Primary endpoint: Week 16 ACR50